Sysmex (OTCMKTS:SSMXY) Sees Strong Trading Volume - What's Next?

Key Points

• Sysmex Corporation experienced a significant increase in trading volume, with 420,220 shares traded, representing a 301% increase from the prior session.
• Wall Street analysts have adjusted Sysmex's rating from a "strong sell" to a "hold", reflecting a more favorable outlook despite earlier underperformance in earnings.
• The company's recent quarterly earnings report showed a net margin of 9.35% and revenue of $717.09 million, falling short of analysts' expectations.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) saw an uptick in trading volume on Wednesday . 420,220 shares were traded during trading, an increase of 301% from the previous session's volume of 104,850 shares.The stock last traded at $12.24 and had previously closed at $12.21.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Sysmex from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, Sysmex has a consensus rating of "Hold".

Sysmex Stock Up 0.3%

The company has a market cap of $7.71 billion, a price-to-earnings ratio of 24.50 and a beta of 1.10. The firm's fifty day simple moving average is $13.78 and its 200 day simple moving average is $16.33. The company has a current ratio of 3.37, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.07). Sysmex had a net margin of 9.35% and a return on equity of 10.20%. The business had revenue of $717.09 million during the quarter, compared to analyst estimates of $807.27 million. Sell-side analysts predict that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.